Yves is a veteran marketing and sales professional with more than 30 years in the healthcare industry and extensive experience negotiating licensing and collaboration agreements with large pharmaceutical companies, biotechnology companies and institutions. Prior to joining Alethia, Yves was Senior Vice President, Business Development for LAB International Inc. since October 2003, subsequent to the acquisition of Seyvika Pharmaceuticals for which he was the founder. Prior, he held the position of Vice-President, Business Development and Commercialization at Theratechnologies, and also held the position of Director of Business Development and Senior Marketing Manager, Pharmaceuticals Product Division, for Abbott Laboratories Ltd. He also had the opportunity to work for Glaxo Canada and Miles Laboratories Canada in management positions of increasing responsibility including sales management, marketing, business unit management and strategic development. Yves has been and still is a member of the Board of Directors of several organizations.

Mario was involved in the creation of Alethia in 2002. In his current position, he oversees Alethia’s operations including research and development, pre-clinical studies, collaborations with Universities . Prior, he acted as President of the Clinical Genomics Unit at SignalGene. Prior to joining SignalGene, Mario served as Director, Biotechnology at T2C2/Bio, a leading venture capital fund in Montréal. Earlier in his career, he acted as Director, Molecular Genetics of Algène Biotechnologies. Mario holds a Ph.D. degree in molecular biology from l’Université de Montréal and was an NSERC and FRSQ post-doctoral fellow at McGill University.

Christopher J. Morl, M.B.A., B.Sc. (Hons), is miRagen’s Chief Business Officer.  Mr. Morl has more than 25 years of experience in strategic and operational roles in private biotechnology and multi-national pharmaceutical companies.  Prior to joining miRagen, he was an independent consultant and the acting Chief Financial Officer at Alethia Biotherapeutics, where he currently serves as an Independent Director. Mr. Morl was formerly the Chief Operating Officer at Ambit Biosciences Corporation, an oncology-focused biotechnology company engaged in discovering and developing targeted small molecule kinase inhibitors.  While at Ambit, he delivered a partnership on the lead program, divested the KinomeScan screening business and worked with the CEO to raise equity and venture debt financing and file an IPO.  He also served as Chief Business Officer with responsibility for Finance, Corporate Development and the KinomeScan screening business. Prior to Ambit, Mr. Morl served as Vice President of Business Development at Agensys Inc., a privately- owned biotechnology company acquired by Astellas.  At Agensys, he was responsible for corporate development where, in addition to delivering a series of partnership and licensing arrangements, he led the initiative that resulted in the acquisition by Astellas.  Prior to joining Agensys, he served for 20 years in positions of increasing responsibility in research, sales, marketing, business development and county/general management at GlaxoSmithKline. Mr. Morl earned a B.Sc. (Hons) in Applied Biology and Pharmacology from the University of London (UK) and an M.B.A. from Cranfield School of Management (UK).

Gilles is responsible for drug discovery at Alethia. Gilles started his career as group leader, drug development unit at SignalGene. He has devoted his career to research and discovery of new drugs for the treatment of cancer where he participated in the development of new antiestrogens as well as supervised the preclinical development of novel anti-angiogenic factors. Gilles holds a Ph.D. degree in biochemistry from McGill University and was a post-doctoral fellow at the Molecular Oncology Group, McGill University Health Center.

Jean was most recently Executive Vice-President and Chief Medical Officer of GeminX Pharmaceuticals from 2002 until its acquisition by Cephalon in April 2011.  In that role Jean oversaw the clinical development of the bcl2 inhibitor obatoclax and lead all clinical, regulatory and drug development functions within the company as well as playing a central role in business development and investor relations.  Jean obtained his MD degree from the University of Montreal, completed his internal medicine residency at the Montreal General Hospital before spending 4 years at the National Cancer Institute in Bethesda, MD where he obtained board certification in medical oncology as well as basic research training in cellular and molecular biology of cancer.  Prior to GeminX, Jean held positions of increasing responsibilities at Sanofi and GSK where he played important roles in the development and registration of several products including oxaliplatin, rasburicase nd Bexxar.

Janique is responsible for maintaining and building Alethia’s intellectual property portfolio and strategy worldwide. Janique holds a Ph.D. degree in molecular biology from the University of Montreal. She is a patent agent registered for practice in Canada and in United States. Before joining Alethia, Janique was a member of the Technology and Intellectual Property Practice Group at Fasken Martineau DuMoulin from 2009 to 2011 and a member of the Life Science practice group at BCF from 2001 to 2009. She made partner in both law firms and acted as Alethia’s intellectual property advisor during that period.

Julie is overseeing the preclinical development program of Alethia Biotherapeutics’ lead candidates. She has more than 15 years of experience in the pharmaceutical industry with extensive experience in preclinical and clinical development projects. Prior to joining Alethia Biotherapeutics, she held various progressive positions at BELLUS Health/Neurochem Inc. during a 14-year period to Director of Preclinical Research and Clinical Research. Julie is a pharmacist and holds a Ph.D. in Pharmaceutical Sciences from the Université de Montréal with a focus in pharmacokinetic and pharmacodynamic modeling.